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Introduction: PIONEER (NCT01185314) was a prospective, mul-
tinational, epidemiological study of epidermal growth factor recep-
tor (EGFR) mutations in patients from Asia with newly diagnosed 
advanced lung adenocarcinoma.
Methods: Eligible patients (aged ≥20 years) had untreated stage 
IIIB/IV adenocarcinoma. The EGFR mutation status (primary end 
point: positive, negative, or undetermined) of tumor samples (biopsy, 
surgical specimen, or cytology) was determined (Scorpion amplifica-
tion refractory mutation system). EGFR mutation frequency was cal-
culated and compared between demographic and clinical subgroups.
Results: Of 1482 patients from seven Asian regions, 43.4% of 
patients were female, median age was 60 years (range, 17–94), 
and 52.6% of patients were never-smokers. EGFR mutation status 
was evaluable in tumors from 1450 patients (97.8%) (746 [51.4%] 
positive; 704 [48.6%] negative). Country, sex, ethnicity, smoking 
status, pack-years (all p < 0.001), disease stage (p = 0.009), and 
histology type (p = 0.016) correlated significantly with EGFR muta-
tion frequency. Mutation frequency was 61.1% in females, 44.0% 
in males; lower in patients from India (22.2%) compared with other 
areas (47.2%–64.2%); highest among never-smokers (60.7%); 
and decreased as pack-year number increased (>0–10 pack-years, 
57.9%; >50 pack-years, 31.4%) (similar trend by sex). Ethnic group 
(p < 0.001) and pack-years (p < 0.001) had statistically significant 
associations with mutation frequency (multivariate analysis); sex was 
not significant when adjusted for smoking status.
Conclusion: PIONEER is the first prospective study to confirm 
high EGFR mutation frequency (51.4% overall) in tumors from 
Asian patients with adenocarcinoma. The observed high mutation 
frequency in demographic/clinical subgroups compared with white 
populations suggests that mutation testing should be considered for 
all patients with stage IIIB/IV adenocarcinoma, even males and regu-
lar smokers, among Asian populations.
Key Words: Epidermal growth factor receptor mutation, epidemiol-
ogy, Asian, Adenocarcinoma, Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 154–162)
Non–small-cell lung cancer (NSCLC) comprises approxi-mately 80% to 85% of all lung cancers,1 and the major-
ity of patients present with advanced or metastatic disease.2 
Several phase III studies have demonstrated the clinical effi-
cacy of the epidermal growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) gefitinib and erlotinib compared 
with chemotherapy against advanced NSCLC when used as 
 first-line treatment for patients whose tumors harbor activat-
ing EGFR mutations.3–8 Several clinical practice guidelines 
now recommend EGFR mutation testing before initiation of 
first-line therapy for advanced NSCLC.9–11
The frequency of EGFR mutation among Asian 
(Japanese) NSCLC populations is approximately 30%12 
compared with approximately 20% in white populations.13,14 
Among clinical subgroups, the frequency of mutation in Asian 
males and smokers is low in comparison with Asian females 
and never-smokers15–17; however, even these  low-frequency 
subgroups have a higher prevalence of EGFR mutations 
compared with broad white populations.15–17 To date, epide-
miological studies of EGFR mutation frequency have been 
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performed in white populations, but no large epidemiological 
studies have provided prospective EGFR mutation frequency 
data in Asian populations, other than Japanese. In addition, no 
large epidemiological studies have compared the frequency of 
EGFR mutations in patients of different Asian ethnicities and 
it is still to be confirmed whether the traditional view of a 
higher frequency of EGFR mutation in Asian patients applies 
to all subgroups of Asian patients. Indeed, current thinking on 
EGFR mutation testing among many clinicians is still gov-
erned largely by the idea of the clinically selected Iressa Pan-
Asia Study (IPASS) population,3 with patients of female sex, 
adenocarcinoma histology, never-smoking status, and Asian 
ethnicity considered for testing. It is important to investigate 
this assumption by determining the prevalence of EGFR muta-
tions among different ethnic and clinical subgroups of Asian 
patients, the results of which will help to optimize the identi-
fication of patients likely to benefit from EGFR-TKI therapy.
A molecular epidemiology study in Asian patients 
with advanced NSCLC of adeno histology to assess EGFR 
mutation status (PIONEER) was an epidemiological study 
planned to provide prospective EGFR mutation data in 
patients from Asia with newly diagnosed adenocarcinoma 
NSCLC. In this study, we report the EGFR mutation fre-
quency of the overall PIONEER population. The influence of 
demographic/clinical factors on EGFR mutation frequency 
was also investigated.
MATERIALS AND METHODS
Study Design
PIONEER (NCT 01185314) was a prospective, multina-
tional, epidemiological study of EGFR mutation status in patients 
from Asia with newly diagnosed advanced (stage IIIB or IV) 
NSCLC of adenocarcinoma histology. The primary objective of 
the study was to assess the overall EGFR mutation frequency. 
Secondary objectives were to investigate the correlation between 
EGFR mutation status and demographic and clinical factors; to 
investigate the attrition rates of EGFR mutation testing; and to 
investigate the correlation of EGFR mutation status between 
histology and cytology for patients who provided both samples.
Patients
Eligible patients were aged 20 years or older, with his-
tological/cytological confirmed advanced (stage IIIB/IV), treat-
ment-naïve, adenocarcinoma NSCLC. Data collected included 
date of the first diagnosis of NSCLC, histological type, American 
Joint Committee on Cancer disease stage, and number of organs 
with metastases. Availability of tumor samples (biopsy, surgical 
specimen, or cytology) was an inclusion criterion in the study.
The study was conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
Harmonisation Guidelines for Good Clinical Practice, appli-
cable regulatory requirements, and AstraZeneca’s policy on 
bioethics, and was approved by the Ethics Committees of all 
study centers. All patients provided written informed consent 
before the initiation of data collection and sample testing.
Assessments
Detection of EGFR Mutations
Acquisition, preparation, and processing of tumor mate-
rial were performed in line with routine clinical practice at 
participating hospital laboratories. Tumor EGFR mutation 
status was determined by analyzing DNA extracted from 
 formalin-fixed, paraffin-embedded archival tumor tissue 
(using validated methods previously published by Fukuoka 
et al.18) or from cytology samples (including fine-needle aspi-
rates and bronchial washings). Samples underwent central, 
histopathological review to ensure that they were adequate for 
use and where appropriate, hematoxylin and eosin-stained tis-
sue was classified by suitably qualified pathologists according 
to the most recent World Health Organization classification. 
Samples considered suitable for downstream biomarker anal-
ysis were progressed to biomarker analysis (on the basis of 
quality, sample source, and tumor content [>100 tumor cells]). 
All samples were tested by using an amplification refractory 
mutation system (ARMS)-based EGFR mutation detection kit 
(Scorpion ARMS IVD2; Qiagen, Crawley, United Kingdom). 
The ARMS IVD2 kit is able to detect 29 mutations: three in 
exon 18 (G719A, G719S, and G719C; the kit was unable to 
distinguish between these subtypes, which are referred to as 
G719X hereafter), 19 deletions in exon 19, two mutations in 
exon 20 (S768I, T790M), three insertions in exon 20, and two 
mutations in exon 21 (L858R, L861Q). The EGFR mutation 
status of each patient’s tumor was assessed from the individual 
status of all EGFR mutation types and recorded as one of the 
following: positive (mutation detected for at least one of the 
mutation types assayed), negative (no mutation detected in any 
of the mutation types assayed), or undetermined/unknown (a 
positive or negative result could not be determined as per lab-
oratory assessment [assay fail, insufficient DNA, fail because 
of assay criteria, or no/insufficient sample]).
Statistical Analyses
The overall distribution of EGFR mutation status (pri-
mary end point) was summarized as the number of patients 
in the per-protocol (PP) population (all patients who did not 
significantly deviate from the study protocol) classified in 
each of the three mutation status categories (positive, nega-
tive, or undetermined/unknown). Percentages of patients in 
the positive and negative groups were calculated with cor-
responding 95% confidence intervals (CIs) using the Wilson 
score method, both overall and for demographic/clinical sub-
groups, including country/region, sex, ethnic group, smoking 
status, smoking pack-years, disease stage, and histology type. 
Patients with tumors of undetermined EGFR mutation status 
were not included in these calculations. The specific EGFR 
mutations detected by the ARMS kit were only summarized, 
with no formal statistical comparison performed.
Frequency of EGFR mutation was compared between 
demographic and clinical subgroups with the use of 
χ2/Fisher’s exact test, with no correction made for multiple 
testing. To best predict EGFR mutation frequency, factors 
with p less than 0.05 in the univariate analysis were further 
analyzed by multivariate logistic regression (at 1% signifi-
cance level because of the large data set).
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To investigate any correlation of EGFR mutation sta-
tus between histology and cytology for patients who provided 
both types of samples, the probability (and 95% CIs) of agree-
ment between sample types was calculated using the Wilson 
score method and Cohen’s κ coefficient.
Sample size was calculated to obtain an accurate esti-
mate of the proportion of patients with EGFR mutation-posi-
tive tumors. Assuming a percentage of 40%, more than 1047 
samples were required to ensure a 95% CI of less than ±3% 
(Wilson score method). Taking into account patients with 
tumors of undetermined status, an overall sample size of 1270 
was chosen.
RESULTS
Patients
From September 29, 2010 to July 31, 2011, 1510 
patients were enrolled from 51 investigational sites in seven 
Asian countries/regions (China mainland, Hong Kong, India, 
Philippines, Taiwan, Thailand, and Vietnam) (Fig. 1). Of these 
patients, 1482 had no important protocol deviations, had 
samples available for mutation analysis, and were included in 
the PP population. Of note, three patients were less than 20 
years old, deviating from the inclusion criteria that patients 
should be 20 years or older; however, this was considered a 
minor deviation and these patients were included in the PP 
population.
Overall demography/clinical characteristics for the 
PP population are summarized in Table 1; 43.4% (643 of 
1482) were female, median age was 60 years (range, 17–94 
FIGURE 1.  Study flow diagram. aTwo patients had major 
protocol deviations: one patient did not have histologically or 
cytologically confirmed NSCLC, and one patient had received 
previous treatment for NSCLC. Three patients were <20 years 
old and therefore violated the study inclusion criteria. This 
deviation was considered to be minor and these patients were 
subsequently included in the PP population. bFour patients 
had tumor samples that were not tested for EGFR mutations: 
two biopsy samples were lost after pathological reading, one 
sample did not have a clot for preparing a tissue block, and 
the DNA concentration of one block was insufficient for test-
ing. EGFR, epidermal growth factor receptor; NSCLC, non–
small-cell lung cancer; PP, per-protocol population.
TABLE 1.  Key Demographic and Clinical Characteristics  
(PP Population)
PP Population (n = 1482)
Country/region, n (%)
  China 747 (50.4)
  Hong Kong 170 (11.5)
  India 81 (5.5)
  Philippines 66 (4.5)
  Taiwan 178 (12.0)
  Thailand 119 (8.0)
  Vietnam 121 (8.2)
Median age, yrs (range) 60 (17–94)
Female sex, n (%) 643 (43.4)
Ethnic group, n (%)
  Chinese 1093 (73.8)
  Indian 82 (5.5)
  Japanese 1 (0.1)
  Kinh 121 (8.2)
  Filipino 63 (4.3)
  Thai 119 (8.0)
  Mixed/others 3 (0.2)
Smoking history,a n (%)
  Never-smoker 779 (52.6)
  Ex-smoker 310 (20.9)
  Occasional smoker 66 (4.5)
  Regular smoker 327 (22.1)
Smoking pack-years, n (%)
  0 779 (52.8)
  >0–10 123 (8.3)
  >10–20 138 (9.4)
  >20–30 153 (10.4)
  >30–40 113 (7.7)
  >40–50 62 (4.2)
  >50 106 (7.2)
Time from diagnosis of NSCLC, months
  <6 1398 (94.3)
  6–12 35 (2.4)
  >12 49 (3.3)
Stage classification
  IIIB 281 (19.0)
  IV 1164 (78.5)
  Other 37 (2.5)
Histology type
  Adenocarcinoma (NOS) 1406 (94.9)
  Adenocarcinoma bronchoalveolar 76 (5.1)
Sample tissue type
  Primary tumor 1032 (69.6)
  Metastases 412 (27.8)
  Others 38 (2.6)
aSmoking history definitions: never-smoker (patients who had never smoked 
cigarettes in their lifetime); ex-smoker (patients who had previously smoked but no 
longer smoked); occasional smoker (patients who smoked, but not every day); and 
regular smoker (patients who smoked every day).
NSCLC, non–small-cell lung cancer; PP, per-protocol; NOS, not otherwise specified.
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years), and 52.6% (779 of 1482) were never-smokers. Nearly 
 three-quarters of patients (73.8% [1093 of 1482]) were of 
Chinese ethnicity.
EGFR Mutation Analyses
Sample Flow Attrition Rates
Of 1486 patients with no important protocol devia-
tions, tumor samples from four were not tested: two biopsy 
samples were lost after pathological reading, one sample did 
not have a clot for preparing a tissue block, and the DNA con-
centration of one block was insufficient for testing. Of the 
remaining 1482 samples tested, 169 (11.4%) were cytology 
samples. In the overall PP population, EGFR mutation anal-
ysis was successful in samples from 1450 of 1482 patients 
(97.8%; 95% CI, 97.0%–98.5%); 32 of 1482 (2.2%; 95% 
CI, 1.5%–3.0%) were undetermined (unknown), of which 
eight were cytology samples. Among the 1450 evaluable 
samples, 746 (51.4%; 95% CI, 48.9–54.0) were EGFR muta-
tion positive and 704 (48.6%; 95% CI, 46.0–51.1) were EGFR 
mutation negative.
EGFR Mutation Test Time
Of patients with a known time interval between phy-
sicians requesting and obtaining a test result (n = 1475), the 
mean (SD) time interval for reporting the test was 17.6 (13.3) 
days (median, 15.0; range, 1–148 days); for the majority of 
patients (1168; 79.2%), the time interval was less than 21 days.
Associations between EGFR Mutation Frequency and 
Demographic/Clinical Factors
Tumor EGFR mutation frequency for patients in demo-
graphic/clinical subgroups is presented in Table 2. Factors 
with a statistically significant association with EGFR muta-
tion status (χ2 or Fisher’s exact test) were country, sex, eth-
nicity, smoking status, smoking pack-years (all p < 0.001), 
disease stage (p = 0.009), and histology type (p = 0.016), and 
are briefly summarized below. Caution is advised when inter-
preting results of these univariate analyses because individual 
demographic/clinical factors may be influenced by others and 
therefore may not represent a true effect of that variable:
Country/Region—EGFR mutation frequency was high-
est in patients from Vietnam (64.2% [77 of 120]) and lowest in 
patients from India (22.2% [16 of 72]) (other countries 47.2% 
[76 of 161] to 62.1% [108 of 174]).
Sex—EGFR mutation frequency was significantly 
higher in females (61.1% [384 of 628]) than males (44.0% 
[362 of 822]).
Ethnic Group—EGFR mutation frequency was highest 
for those of Kinh (Vietnamese) ethnicity (64.2% [77 of 120]) 
and lowest for those of Indian ethnicity (21.9% [16 of 73]).
Smoking Status—EGFR mutation frequency was high-
est among never-smokers (60.7% [462 of 761]) compared 
with ex-smokers (43.2% [130 of 301]), occasional smokers 
(51.6% [33 of 64]), or regular smokers (37.3% [121 of 324]).
Smoking Pack-Years—EGFR mutation frequency was 
highest among never-smokers (60.7%) and decreased as 
 pack-year number increased (>0–10 pack-years: 57.9%; >50 
pack-years: 31.4%). A similar trend was observed by sex: males 
(0–10 pack-years: 55.9% [161 of 288], >10–30 pack-years: 
46.6% [123 of 264], and >30 pack-years: 28.2% [74 of 262]); 
females (0–10 pack-years: 62.5% [371 of 594], >10–30 pack-
years: 37.5% [9 of 24], and >30 pack-years: 40.0% [4 of 10]).
Disease Stage—EGFR mutation frequency was signifi-
cantly higher among patients with stage IV disease (53.5% 
[612 of 1144]) compared with IIIB (43.2% [117 of 271]) or 
other stage (48.6% [17 of 35]).
Histology Type—EGFR mutation frequency was signifi-
cantly higher among patients with adenocarcinoma not other-
wise specified histology (52.2% [718 of 1376]) compared with 
adenocarcinoma bronchoalveolar histology (37.8% [28 of 74]).
Factors not significantly correlating with EGFR muta-
tion frequency were age (p = 0.565), time from diagnosis 
(p = 0.612), existence of malignant pleural effusion (p = 
0.265), primary tumor stage (tumor staging T1-TX; p = 
0.454), regional lymph node involvement (p = 0.075), and 
tumor grade (p = 0.369).
Multivariate logistic regression (with 1% significance 
level) identified ethnicity (p < 0.001) and smoking pack-years 
(p < 0.001) to be independent predictive factors for EGFR 
mutation status (Table 3). When stratified by smoking status or 
pack-years, sex was no longer found to be significant (Fig. 2).
Individual mutation types, including multiple muta-
tions, are summarized in Table 4. Of the 1450 evaluable 
samples, 671 (46.3%) harbored activating (sensitizing) 
mutations alone, 42 (2.9%) had resistance mutations alone, 
and 33 (2.3%) had a combination of activating and resis-
tance mutations. The most common mutations detected 
were deletion in exon 19 (deletion alone 22.1% [321 of 
1450]; alone and in combination with others 24.3% [352 of 
1450]) and L858R point mutation in exon 21 (L858R alone 
20.9% [303 of 1450]; alone and in combination with oth-
ers 22.9% [332 of 1450]). Tumors from 21 patients (1.4%) 
harbored T790M resistance mutations, of which five (0.3%) 
had T790M alone.
Correlation of EGFR Mutation Status 
between Histology and Cytology for 
Patients Who Provided Both Samples
In total, 23 patients (1.5% of PP population) provided 
both histology and cytology samples for mutation analysis. 
The EGFR mutation status (and specific mutations found) of 
matched histology and cytology samples were concordant for 
21 patients (positive n = 13, negative n = 8; 91.3% concor-
dance [Wilson score 95% CI, 73.2%–97.6%; κ coefficient 
0.817]). Matched samples from two patients were discordant 
(one patient’s samples were positive for histology and nega-
tive for cytology, with the other patient having a reverse of 
this result).
DISCUSSION
In PIONEER, the first epidemiological study of EGFR 
mutation frequency across Asian countries/regions, approxi-
mately half of the unselected patients with adenocarci-
noma NSCLC had tumors that harbored EGFR mutations. 
Frequency of tumor mutation was significantly lower in Indian 
patients compared with other countries, and at 22.2%, was 
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more comparable with the frequency for a broad white popu-
lation (approximately 20%)13 than to the East Asian countries/
regions in the study (approximately 47–64%), or the approxi-
mately 30% and approximately 36% reported in Japanese and 
Korean patients, respectively.12,19 Interestingly, a higher tumor 
mutation frequency of 44% was reported in a similarly sized 
(n = 75) adenocarcinoma population of Indian patients in a 
study by Sahoo et al.,20 using Scorpion ARMS polymerase 
TABLE 2. EGFR Mutation Frequency for Demographic and Clinical Characteristic Subgroups (PP Population)
N
EGFR Mutation-Positive EGFR Mutation-Negative
pn (%) 95% CI n (%) 95% CI
Country/region <0.001
  China 741 372 (50.2) 46.6–53.8 369 (49.8) 46.2–53.4
  Hong Kong 161 76 (47.2) 39.6–54.9 85 (52.8) 45.1–60.4
  India 72 16 (22.2) 14.2–33.1 56 (77.8) 66.9–85.8
  Philippines 65 34 (52.3) 40.4–64.0 31 (47.7) 36.0–59.6
  Taiwan 174 108 (62.1) 54.7–68.9 66 (37.9) 31.1–45.3
  Thailand 117 63 (53.8) 44.8–62.6 54 (46.2) 37.4–55.2
  Vietnam 120 77 (64.2) 55.3–72.2 43 (35.8) 27.8–44.7
Sex <0.001
  Female 628 384 (61.1) 57.3–64.9 244 (38.9) 35.1–42.7
  Male 822 362 (44.0) 40.7–47.5 460 (56.0) 52.5–59.3
Ethnic group <0.001
  Chinese 1074 556 (51.8) 48.8–54.7 518 (48.2) 45.3–51.2
  Indian 73 16 (21.9) 14.0–32.7 57 (78.1) 67.3–86.0
  Japanese 1 0 (0.0) 0.0–79.3 1 (100.0) 20.7–100.0
  Kinh 120 77 (64.2) 55.3–72.2 43 (35.8) 27.8–44.7
  Filipino 62 31 (50.0) 37.9–62.1 31 (50.0) 37.9–62.1
  Thai 117 63 (53.8) 44.8–62.6 54 (46.2) 37.4–55.2
  Mixed/others 3 3 (100.0) 43.9–100.0 0 (0.0) 0.0–56.1
Smoking historya <0.001
  Never-smoker 761 462 (60.7) 57.2–64.1 299 (39.3) 35.9–42.8
  Ex-smoker 301 130 (43.2) 37.7–48.8 171 (56.8) 51.2–62.3
  Occasional smoker 64 33 (51.6) 39.6–63.4 31 (48.4) 36.6–60.4
  Regular smoker 324 121 (37.3) 32.3–42.7 203 (62.7) 57.3–67.7
Smoking pack-years <0.001
  0 761 462 (60.7) 57.2–64.1 299 (39.3) 35.9–42.8
  >0–10 121 70 (57.9) 48.9–66.3 51 (42.1) 33.7–51.1
  >10–20 135 62 (45.9) 37.7–54.3 73 (54.1) 45.7–62.3
  >20–30 153 70 (45.8) 38.1–53.7 83 (54.2) 46.3–61.9
  >30–40 110 29 (26.4) 19.0–35.3 81 (73.6) 64.7–81.0
  >40–50 60 17 (28.3) 18.5–40.8 43 (71.7) 59.2–81.5
  >50 102 32 (31.4) 23.2–40.9 70 (68.6) 59.1–76.8
Stage classification 0.016
  IIIB 271 117 (43.2) 37.4–49.1 154 (56.8) 50.9–62.6
  IV 1144 612 (53.5) 50.6–56.4 532 (46.5) 43.6–49.4
  Other 35 17 (48.6) 33.0–64.4 18 (51.4) 35.6–67.0
Histology type 0.009
  Adenocarcinoma 
(NOS)
1376 718 (52.2) 49.5–54.8 658 (47.8) 45.2–50.5
  Adenocarcinoma 
bronchoalveolar
74 28 (37.8) 27.6–49.2 46 (62.2) 50.8–72.4
p Values are from χ2 or Fischer’s exact test, refer to overall comparisons across all subgroups, and are not corrected for multiple testing. All patients had stage IIIB/IV disease; 
however, some provided tumor samples at an earlier stage of their disease, and were therefore classified as other. Caution is advised when interpreting the results of these univariate 
analyses as the results of an individual demographic and clinical factor may be influenced by the others and may therefore not represent a true effect of that variable.
aSmoking history definitions: never-smoker (patients who had never smoked cigarettes in their lifetime); ex-smoker (patients who had previously smoked but no longer smoked); 
occasional smoker (patients who smoked, but not every day); and regular smoker (patients who smoked every day).
CI, confidence interval; PP, per-protocol; NOS, not otherwise specified; EGFR, epidermal growth factor receptor.
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chain reaction. However, only 90 of 220 tumor samples could 
be histologically subclassified, which may have resulted in 
potential bias. In contrast, the large data set and consistent 
use of mutation test methodology in PIONEER permitted 
comprehensive and reliable subgroup analysis. In PIONEER, 
a patient’s ethnicity and smoking status/pack-years were inde-
pendent predictive factors for tumor EGFR mutation status. Of 
note, there was no association between sex and tumor EGFR 
mutation status when results were stratified by smoking status.
Generally, female sex, adenocarcinoma histology, 
never-smoking status, and Asian ethnicity are considered the 
most important factors associated with EGFR mutation and 
response to EGFR-TKIs.21 In PIONEER, univariate analyses 
showed that country, sex (subsequently negated when stratified 
by smoking status), ethnic group, smoking status,  pack-years, 
disease stage, and adenocarcinoma histology type all had a 
statistically significant association with EGFR mutation sta-
tus (note that our study was ongoing before the publication 
of the new adenocarcinoma classification system).22 The high-
est frequency of EGFR mutation was among female never-
smokers, in agreement with previous studies.17,23–25 However, 
tumor EGFR mutations can be found in patients with clinical 
characteristics other than female sex, adenocarcinoma his-
tology, never-smoking status, or Asian ethnicity. Indeed, the 
frequency of EGFR mutation in tumors from Asian males in 
PIONEER was 44% (ARMS), in sharp contrast to the 8.2% 
reported in a comparable European male population (DNA 
sequencing).14 Similarly, frequency of EGFR mutation in Asian 
 heavy-smokers was approximately 30% in PIONEER, much 
higher than the 5.8% observed in European heavy-smokers.14 
Thus, physicians should not discount these other populations 
from EGFR mutation testing on the basis of clinical charac-
teristics. In a large, retrospective U.S. study of 2142 patients 
with stage I to IV NSCLC, EGFR mutations in tumors from 
former/current smokers represented 40% of all mutations 
detected (direct sequencing; 201 of 503; 95% CI, 36%–44%), 
and those from men represented 31% (157 of 503; 95% CI, 
27%–35%)13; if only female  never-smokers had been tested, 
57% of mutation-positive tumors would have remained unde-
tected. In PIONEER, more than 50% of patients with EGFR 
mutation-positive tumors came from subpopulations other 
than female never-smokers. These data highlight that EGFR 
mutation testing is warranted even in males and smokers, 
particularly in Asian populations, and emphasize that EGFR 
mutation status can only be confirmed by performing EGFR 
mutation testing. EGFR-TKI efficacy in non-Asian patients 
with EGFR mutation-positive NSCLC was demonstrated in the 
phase III European Tarceva versus Chemotherapy (EURTAC) 
study.7 This study of 173 European white patients with EGFR 
mutation-positive tumors (DNA sequencing) reported signifi-
cantly longer progression-free survival (PFS) with first-line 
erlotinib (n = 86; 9.7 months) compared with chemotherapy (n 
= 87; 5.2 months) (hazard ratio [HR], 0.37; 95% CI, 0.25–0.54; 
p < 0.0001), with benefit in both female (n = 126; PFS HR, 
0.35; 95% CI, 0.22–0.55) and male subgroups (n = 47; PFS 
HR, 0.38; 95% CI, 0.17–0.84). These data further strengthen 
the rationale for routine assessment of tumor EGFR mutations 
in all patients (where possible) before initiation of NSCLC 
therapy. Indeed, recent molecular testing guidelines copub-
lished by three societies recommended the use of EGFR 
mutation testing to guide patient selection for therapy with 
an EGFR inhibitor, in all patients with advanced-stage adeno-
carcinoma, regardless of sex, race, smoking history, or other 
clinical risk factors, and to prioritize EGFR testing over other 
molecular predictive tests.26 In PIONEER, the success rate 
(known positive or negative result) of EGFR mutation analysis 
was very high at 97.8%, and only 2.2% of patients had tumor 
samples for which mutation status could not be determined. 
This high success rate is very encouraging as it indicates that 
even though the acquisition, preparation, and processing of 
tumor material varied between test centers/participating labo-
ratories because of differences in routine clinical practice, the 
quality of most samples was such that mutation testing was 
successful and a definite result obtained. The high success rate 
also indicates that the in vitro diagnostic mutation ARMS kit 
used throughout the study was suitable for a range of samples 
where the collection method was not standardized, highlight-
ing its suitability for adoption/routine use at local test centers. 
Indeed, previous studies have found ARMS to be successful 
at detecting EGFR mutations in a variety of sample types, 
including those of cytological origin, with a reported increase 
in detection of EGFR mutations with ARMS when compared 
with direct sequencing.27–29 Although the success rate of muta-
tion testing in PIONEER was very high, the median time 
interval between requesting and reporting a result was 15.3 
days; not ideal from a clinical perspective. However, EGFR 
TABLE 3.  Multivariate Logistic Regression Analysis for EGFR Mutation Status (PP Population)
Variable Contrast
Regression Coefficient 
Estimate SE
Odds Ratio Estimate 
(95% CI) p
Intercept 0.431 0.075
Ethnic groupa Indian vs. Chinese −1.437 0.303 0.24 (0.13–0.43) <0.001
Thai vs. Chinese 0.135 0.202 1.14 (0.77–1.70)
Kinh vs. Chinese 0.717 0.212 2.05 (1.35–3.10)
Filipino vs. Chinese 0.070 0.274 1.07 (0.63–1.83)
Pack-years >10–30 vs. 0–10 −0.683 0.140 0.51 (0.38–0.66) <0.001
>30 vs. 0–10 −1.343 0.154 0.26 (0.19–0.35)
Total number of patients in the regression analysis was 1438.
aJapanese (n = 1) and mixed/others (n = 3) were excluded from ethnic groups because of the very small patient numbers.
CI, confidence interval; EGFR, epidermal growth factor receptor; PP, per-protocol; SE, standard error.
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mutation testing was not performed routinely in some partici-
pating countries, and performing tests solely for the experi-
mental purposes of our study will have exacerbated this time 
interval. Commercial test centers routinely performing tests 
are currently reporting turnaround times of 8 to 10 days30; 
however, even this may not be satisfactory, given that patients 
need access to the most appropriate treatment as quickly as 
possible. Research into more rapid mutation identification, 
such as allele-specific testing, may help to reduce this waiting 
period and provide more rapid access to appropriate personal-
ized therapies. Mutation test results were concordant for the 
majority of patients in PIONEER who provided matched his-
tology and cytology samples, indicating that cytology samples 
could be considered for mutation testing if tumor biopsy sam-
ples are not available. However, the small number of samples 
(n = 23) limits the interpretation of these findings, although 
mutation test methodology studies are providing more conclu-
sive evidence which corroborates these data.27
There is currently a need to generate data for a 
 pan-Asian guideline for the management of NSCLC.31 Such 
a guideline has been difficult to establish owing to differences 
in ethnicity and medical care across Asian countries/regions, 
in addition to longer drug approval times compared with the 
European Union and United States.31–34 Lack of standardiza-
tion in testing methodology has also reduced the feasibility 
of large-scale testing.32 However, the consensus from a recent 
meeting to discuss EGFR mutation testing in East Asia rec-
ommended testing all recently diagnosed patients with non-
squamous NSCLC (as is current practice in some centers and 
community practices), and patients with squamous NSCLC 
with clinical features associated with higher prevalence of 
A
B
FIGURE 2.  Combined effect of sex and (A) smoking status 
and (B) pack-years on frequency of EGFR mutation (PP popu-
lation). A, p values for logistic regression model. Smoking 
history definitions: never-smoker (patients who had never 
smoked cigarettes in their lifetime); ex-smoker (patients who 
had previously smoked but no longer smoked); occasional 
smoker (patients who smoked, but not every day); regular 
smoker (patients who smoked every day). B, p values for 
logistic regression model. EGFR, epidermal growth factor 
receptor; PP, per-protocol.
TABLE 4.  Summary of Individual EGFR Mutation Types 
(Including Multiple Mutations)
n %
Patients with an evaluable EGFR mutation test 1450 100.0
Sensitizing mutations alone 671 46.3
  G719X 15 1.0
  G719X, deletion 4 0.3
  G719X, L861Q 2 0.1
  Deletion 321 22.1
  Deletion, L858R 11 0.8
  L858R 303 20.9
  L858R, L861Q 2 0.1
  L861Q 13 0.9
Resistance mutations 42 2.9
  T790M 5 0.3
  S768I 14 1.0
  S768I, exon 20 other (insertion) 4 0.3
  Exon 20 other (insertion) 19 1.3
Combination of sensitizing and resistance mutations 33 2.3
  G719X, deletion, T790M, S768I, L858R, L861Q, 
exon 20 other (insertion)
2 0.1
  G719X, S768I 3 0.2
  G719X, exon 20 other (insertion) 1 0.1
  Deletion, T790M 7 0.5
  Deletion, T790M, L858R 1 0.1
  Deletion, S768I, L858R 1 0.1
  Deletion, S768I, exon 20 other (insertion) 1 0.1
  Deletion, exon 20 other (insertion) 4 0.3
  T790M, L858R 6 0.4
  S768I, L858R 3 0.2
  S768I, L861Q, exon 20 other (insertion) 1 0.1
  L858R, exon 20 other (insertion) 3 0.2
Patients with a negative EGFR mutation test 704 48.6
EGFR, epidermal growth factor receptor.
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EGFR mutations.32 Tissue acquisition and pre-test sample 
evaluation were also considered important steps to increase 
sensitivity/specificity, and thus help standardize mutation 
test methodology. The substantial body of data generated by 
PIONEER therefore has valuable clinical implications for the 
treatment of advanced NSCLC across Asia, and indicates that 
 large-scale testing across countries is feasible, can be stan-
dardized, and can result in a high analysis success rate. Further 
multinational studies are required to help establish guidelines 
and realize these recommendations.
In summary, the observed frequency of tumor EGFR 
mutation in demographic and clinical subgroups of Asian 
patients in PIONEER suggests that EGFR mutation testing 
should be considered for all patients with stage IIIB/IV adeno-
carcinoma NSCLC in an Asian population. Such an approach 
should help ensure the optimal identification and treatment of 
patients whose tumors harbor EGFR mutations.
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